Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia.

Kan X, Zhou G, Zhang F, Ji H, Shin DS, Monsky W, Zheng C, Yang X

Journal for immunotherapy of cancer1 Nov 2022Cited by 22 (Europe PMC)

PMID36450380PMCIDPMC9717415DOI10.1136/jitc-2022-005619PepBankPUB-36450380

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study21

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone21

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

01AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin produced the greatest bioluminescence decrease compared with the other seven groups.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin reduced tumor light signals more than the other seven groups.
Peptide
LTX-315
Outcome
DecreaseTumor bioluminescence
Study
ratn: not reported in source
Rat orthotopic HCC
Comparator
Other seven treatment groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Tumors in this group also presented the most profound decrease in bioluminescence signal intensities and the smallest tumor volumes compared with other seven groups (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038003
02AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin produced the smallest tumors compared with the other seven groups.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin produced smaller tumors than the other seven groups.
Peptide
LTX-315
Outcome
DecreaseTumor volume
Study
ratn: not reported in source
Rat orthotopic HCC
Comparator
Other seven treatment groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Tumors in this group also presented the most profound decrease in bioluminescence signal intensities and the smallest tumor volumes compared with other seven groups (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038004
03AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin increased tumor CD8+ T cells.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin increased CD8+ T cells in tumors.
Peptide
LTX-315
Outcome
IncreaseTumor CD8+ T cells
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
A significant increase of CD8⁺ T cells, CD8⁺/interferon (IFN)-γ⁺ T cells, CD8⁺/tumor necrosis factor (TNF)-α⁺ T cells, and natural killer cells, and a significant decrease of regulatory T cells were observed in the tumors (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038005
04AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin increased tumor CD8+/IFN-γ+ T cells.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin increased CD8+/IFN-γ+ T cells in tumors.
Peptide
LTX-315
Outcome
IncreaseTumor CD8+/IFN-γ+ T cells
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
A significant increase of CD8⁺ T cells, CD8⁺/interferon (IFN)-γ⁺ T cells, CD8⁺/tumor necrosis factor (TNF)-α⁺ T cells, and natural killer cells, and a significant decrease of regulatory T cells were observed in the tumors (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038006
05AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin increased tumor CD8+/TNF-α+ T cells.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin increased CD8+/TNF-α+ T cells in tumors.
Peptide
LTX-315
Outcome
IncreaseTumor CD8+/TNF-α+ T cells
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
A significant increase of CD8⁺ T cells, CD8⁺/interferon (IFN)-γ⁺ T cells, CD8⁺/tumor necrosis factor (TNF)-α⁺ T cells, and natural killer cells, and a significant decrease of regulatory T cells were observed in the tumors (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038007
06AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin increased tumor natural killer cells.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin increased natural killer cells in tumors.
Peptide
LTX-315
Outcome
IncreaseTumor natural killer cells
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
A significant increase of CD8⁺ T cells, CD8⁺/interferon (IFN)-γ⁺ T cells, CD8⁺/tumor necrosis factor (TNF)-α⁺ T cells, and natural killer cells, and a significant decrease of regulatory T cells were observed in the tumors (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038008
07AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin decreased tumor regulatory T cells.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin reduced regulatory T cells in tumors.
Peptide
LTX-315
Outcome
DecreaseTumor regulatory T cells
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
A significant increase of CD8⁺ T cells, CD8⁺/interferon (IFN)-γ⁺ T cells, CD8⁺/tumor necrosis factor (TNF)-α⁺ T cells, and natural killer cells, and a significant decrease of regulatory T cells were observed in the tumors (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038009
08AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with higher plasma IL-2.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with higher plasma IL-2.
Peptide
LTX-315
Outcome
IncreasePlasma IL-2
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038010
09AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with higher plasma IL-12.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with higher plasma IL-12.
Peptide
LTX-315
Outcome
IncreasePlasma IL-12
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038011
10AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with higher plasma IL-18.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with higher plasma IL-18.
Peptide
LTX-315
Outcome
IncreasePlasma IL-18
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038012
11AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with higher plasma IFN-γ.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with higher plasma IFN-γ.
Peptide
LTX-315
Outcome
IncreasePlasma IFN-γ
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038013
12AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with higher tumor IL-2.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with higher tumor IL-2.
Peptide
LTX-315
Outcome
IncreaseTumor IL-2
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038014
13AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with higher tumor IL-18.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with higher tumor IL-18.
Peptide
LTX-315
Outcome
IncreaseTumor IL-18
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038015
14AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with higher tumor IFN-γ.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with higher tumor IFN-γ.
Peptide
LTX-315
Outcome
IncreaseTumor IFN-γ
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038016
15AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with higher tumor TNF-α.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with higher tumor TNF-α.
Peptide
LTX-315
Outcome
IncreaseTumor TNF-α
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038017
16AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with lower plasma IL-4.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with lower plasma IL-4.
Peptide
LTX-315
Outcome
DecreasePlasma IL-4
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038018
17AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with lower tumor IL-4.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with lower tumor IL-4.
Peptide
LTX-315
Outcome
DecreaseTumor IL-4
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038019
18AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with lower plasma IL-10.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with lower plasma IL-10.
Peptide
LTX-315
Outcome
DecreasePlasma IL-10
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038020
19AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rats with HCC, RFH, LTX‑315 and liposomal doxorubicin was associated with lower tumor IL-10.
In plain wordsIn rats, RFH, LTX‑315 and liposomal doxorubicin was associated with lower tumor IL-10.
Peptide
LTX-315
Outcome
DecreaseTumor IL-10
Study
ratn: not reported in source
Rat orthotopic HCC
Outcome group
Immune response · Cancer
Source sentences
Summary
Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038021
20LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In rat HCC cells, RFH, LTX‑315 and liposomal doxorubicin produced the highest apoptotic percentage compared with the other seven groups.
In plain wordsIn cells, RFH, LTX‑315 and liposomal doxorubicin produced more apoptosis than the other seven groups.
Peptide
LTX-315
Outcome
IncreaseApoptotic cells
Study
ratn: not reported in source
Luciferase-labeled rat HCC cells
Comparator
Other seven treatment groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Flow cytometry and MTS assay showed the highest percentage of apoptotic cells and lowest cell viability in the triple combination treatment group compared with other seven groups (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038001
21LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In rat HCC cells, RFH, LTX‑315 and liposomal doxorubicin produced the lowest viability compared with the other seven groups.
In plain wordsIn cells, RFH, LTX‑315 and liposomal doxorubicin produced lower viability than the other seven groups.
Peptide
LTX-315
Outcome
DecreaseCell viability
Study
ratn: not reported in source
Luciferase-labeled rat HCC cells
Comparator
Other seven treatment groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Flow cytometry and MTS assay showed the highest percentage of apoptotic cells and lowest cell viability in the triple combination treatment group compared with other seven groups (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3645038002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.